Literature DB >> 12531807

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies.

Elena Raschi1, Cinzia Testoni, Daniela Bosisio, Maria O Borghi, Takao Koike, Alberto Mantovani, Pier Luigi Meroni.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies (aPLs) and recurrent thrombosis or fetal loss. The thrombophilic state has been partially related to the induction of a proinflammatory and procoagulant endothelial cell (EC) phenotype induced by anti-beta(2)-glycoprotein I (beta(2)-GPI) antibodies that bind beta(2)-GPI expressed on the EC surface. Anti-beta(2)-GPI antibody binding has been shown to induce nuclear factor-kappa B (NF-kappa B) translocation leading to a proinflammatory EC phenotype similar to that elicited by interaction with microbial products (lipopolysaccharide [LPS]) and proinflammatory cytokines (interleukin 1 beta [IL-1 beta], tumor necrosis factor alpha [TNF-alpha]). However, the upstream signaling events are not characterized yet. To investigate the endothelial signaling cascade activated by anti-beta(2)-GPI antibodies, we transiently cotransfected immortalized human microvascular endothelial cells (HMEC-1) with dominant-negative constructs of different components of the pathway (Delta TRAF2, Delta TRAF6, Delta MyD88) together with reporter genes (NF-kappa B luciferase and pCMV-beta-galactosidase). Results showed that both human anti-beta(2)-GPI IgM monoclonal antibodies as well as polyclonal affinity-purified anti-beta(2)-GPI IgG display a signaling cascade comparable to that activated by LPS or IL-1. Delta TRAF6 and Delta MyD88 significantly abrogate antibody-induced as well as IL-1- or LPS-induced NF-kappa B activation, whereas Delta TRAF2 (involved in NF-kappa B activation by TNF) does not affect it. Moreover, anti- beta(2)-GPI antibodies and LPS followed the same time kinetic of IL-1 receptor-activated kinase (IRAK) phosphorylation, suggesting an involvement of the toll-like receptor (TLR) family. Our findings demonstrate that anti-beta(2)-GPI antibodies react with their antigen likely associated to a member of the TLR/IL-1 receptor family on the EC surface and directly induce activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531807     DOI: 10.1182/blood-2002-08-2349

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

1.  Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome.

Authors:  F Conti; C Alessandri; M Sorice; A Capozzi; A Longo; T Garofalo; R Misasi; D Bompane; G R V Hughes; M A Khamashta; G Valesini
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

3.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

4.  Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells.

Authors:  H Zhou; Y Yan; G Xu; B Zhou; H Wen; D Guo; F Zhou; H Wang
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 5.  The dual role of innate immunity in the antiphospholipid syndrome.

Authors:  J Rauch; M Dieudé; R Subang; J S Levine
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 6.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

7.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.

Authors:  Jakub Swadzba; Teresa Iwaniec; Jacek Musial
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

Review 8.  The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management.

Authors:  Richard A Marlar; Sanam Husain
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

9.  Annexin A2 tetramer activates human and murine macrophages through TLR4.

Authors:  Jennifer F A Swisher; Nicholas Burton; Silvia M Bacot; Stefanie N Vogel; Gerald M Feldman
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

Review 10.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.